Viz.ai Expands into Lung Disease to Accelerate Diagnosis and Care for Patients
Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, has announced expanded capabilities for its lung disease software. The new features incorporate natural language processing (NLP) alongside imaging…
Nucleus RadioPharma Boosts Radiopharmaceutical R&D and Production to Address U.S. Supply Chain Challenges
Nucleus RadioPharma announced the development of two new facilities, totaling over 100,000 square feet, in Mesa, Arizona, and Spring House, Pennsylvania. These state-of-the-art sites will integrate research, development, and commercial…
HemoHim Manufacturer Kolmar BNH Receives NAI Classification from U.S. FDA
Kolmar BNH (KRX: 200130), the manufacturer of the immune-boosting health supplement HemoHim, has gained international recognition for its product quality from both the U.S. Food and Drug Administration (FDA) and…
FDA Approves NGS-Based Companion Diagnostic for First Targeted Therapy in Patients with Grade 2 IDH-Mutant Glioma
Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic…
Waltz Health and Noom Partner to Bring a Comprehensive and More Affordable Weight Loss Program to Employers
Waltz Health, a digital health company developing smarter, technology-enabled ways to price, distribute and prescribe medications and Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people…
VSee Health Expands Telehealth Services with New GLP-1 Program to Tackle Obesity and Chronic Disease
VSee Health, Inc. (Nasdaq: VSEE), a leading provider of telehealth services that optimize workflow and enhance patient care, has launched a new program to address obesity and related health risks…
Nuclidium Announces First Patient Imaging in Phase 1 Trial of 61Cu-based Radiotracer for PSMA-positive Prostate Cancer
NUCLIDIUM today announced the successful imaging of the first patient in a Phase 1 clinical trial evaluating its radiotracer candidate as a safe and effective diagnostic and disease-staging tool in…
Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225…
Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases,…
Catalent Releases Open Letter to Customers About Novo Holdings Acquisition
Catalent Affirms Commitment to Customers and Patients Amidst Novo Holdings Acquisition Alessandro Maselli to Remain President and CEO of Catalent Post-Acquisition Catalent, Inc. (NYSE: CTLT), a leader in the development…
BeiGene Gains CHMP Backing for TEVIMBRA® in First-Line Treatment of Gastric and Esophageal Cancers
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® in First-Line Treatment of Gastric, Gastroesophageal, and Esophageal Cancers BeiGene, a global oncology leader, has achieved a significant milestone with the European Medicines…
Bruker Unveils $100 High-Accuracy Plasma Proteome, Advancing Glycoproteomics and Metaproteomics
Bruker Unveils Groundbreaking $100 Plasma Proteomics Platform, Pioneering Advances in Glycoproteomics and Metaproteomics Bruker Corporation has announced a revolutionary leap in 4D-Proteomics™, offering deep, high-fidelity plasma proteomics for just $100…